Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13179006 | 0.96 | CYP2C19 (0.38) | CYP2C19POLBBLMATMCYP3A4 | |
| SCHEMBL17036889 | 0.87 | CYP3A4 (0.36) | CYP2C19POLBBLMATMCYP3A4 | |
| SCHEMBL17036884 | 0.81 | CYP3A4 (0.38) | CYP3A4CA12CA1CA2CA9 | |
| SCHEMBL17036886 | 0.79 | — | — | |
| SCHEMBL17036885 | 0.79 | CA12 (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL2488440 | 0.78 | — | — | |
| SCHEMBL22390227 | 0.78 | TP53 (0.39) | CYP2C19POLBBLMATM | |
| SCHEMBL15833170 | 0.76 | CA12 (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL17036899 | 0.75 | CA12 (0.34) | CA12CA1CA2CA9 | |
| SCHEMBL17719224 | 0.74 | CYP2C19 (0.36) | CYP2C19POLBBLMATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9950001-B2 | Polynucleotides having bioreversible groups | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150238516-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238516-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | RNASE1, NCL, LNPEP | CYP2C19 4723/4885POLB 53/4885BLM 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.